Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.310
-0.040 (-2.96%)
At close: Dec 5, 2025, 4:00 PM EST
1.320
+0.010 (0.76%)
After-hours: Dec 5, 2025, 7:46 PM EST
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,590,600
Market Cap
14.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHIO News
- 11 days ago - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile Corp
- 19 days ago - Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - Newsfile Corp
- 22 days ago - Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director - Newsfile Corp